文献速递性腺与生殖内分泌

前列腺癌患者潮热管理综述

A Review of Hot Flash Management in Patients With Prostate Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本综述基于PubMed和Embase文献检索,概述前列腺癌患者血管舒缩症状的管理。激素治疗(如经皮雌二醇)似乎最有效,但可能发生男性乳房发育;加巴喷丁、奥昔布宁和抗抑郁药等非激素治疗已证实有效但受不良反应限制;非佐林坦等新药需进一步验证。

要点

  • 经皮雌二醇似乎最有效缓解潮热,但可能发生男性乳房发育。
  • 加巴喷丁、奥昔布宁和抗抑郁药已证实有效,但不良反应可限制其应用。
  • 非佐林坦等神经激肽拮抗剂需在前列腺癌人群中进一步验证。

核心结论

  • 临床医生应准备为ADT的不良反应提供循证管理选择。
  • 经皮雌激素等激素选项最可能缓解症状,但可能发生男性乳房发育。
  • 已证实有效的VMS疗法(包括奥昔布宁和抗抑郁药)可能很快被神经激肽拮抗剂补充,后者目前对绝经期潮热疗效显著。

研究设计与样本

  • 本文为小型综述,基于PubMed和Embase数据库的文献检索。

主要发现

  • 激素治疗似乎最有效改善前列腺癌男性令人困扰的潮热。
  • 经皮雌二醇已获充分验证,近期证据提示其作为替代ADT形式可缓解VMS的前景。
  • 已证实有效的非激素治疗包括加巴喷丁、奥昔布宁和各种抗抑郁药,但不良反应可限制其效用。
  • 非药物选项包括认知行为疗法和针灸可能起作用,但需进一步研究明确最佳方案并确认优于安慰剂。

临床怎么用

  • 临床医生应准备为ADT的不良反应提供循证管理选择。
  • 经皮雌激素等激素选项最可能缓解症状,但可能发生男性乳房发育。
  • 已证实有效的VMS疗法(包括奥昔布宁和抗抑郁药)可能很快被神经激肽拮抗剂补充。
  • 非佐林坦等靶向下丘脑体温调节通路的新药需在该人群中进一步验证。
  • 非药物选项(认知行为疗法和针灸)可能起作用,但需进一步研究明确最佳方案并确认优于安慰剂。

局限性

  • 非佐林坦等新药需在该队列中进一步验证。
  • 非药物选项需进一步研究明确最佳方案并确认优于安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Vasomotor symptoms (VMS) including hot flashes are a common toxicity reported by men undergoing androgen deprivation therapy (ADT) and their effective mitigation remains crucial in prostate cancer survivorship. As the understanding of hot flash pathophysiology is refined, novel therapies offer promising benefits to this patient cohort. EVIDENCE ACQUISITION: The following mini-review outlines the landscape of VMS management in patients with prostate cancer as informed by a literature search using the PubMed and Embase databases. EVIDENCE SYNTHESIS: Hormonal therapies appear most effective for ameliorating VMS in men with prostate cancer experiencing bothersome hot flashes. Transdermal estradiol has been well-validated, with recent evidence hinting at its promise as an alternative form of ADT that mitigates VMS. Nonhormonal treatments proven to be efficacious include gabapentin, oxybutynin, and various antidepressants, although their utility can be limited by adverse effects. There is significant interest in novel agents like fezolinetant that target hypothalamic thermoregulatory pathways; however, further validation in this cohort is required. Nonpharmacological options, including cognitive behavior therapy and acupuncture, may also have a role, although further research is needed to clarify the optimal schedule and confirm superiority over placebo. CONCLUSION: Clinicians should be prepared to offer evidence-based management options for the detrimental effects of ADT. Proven therapies for VMS, including oxybutynin and antidepressants, may soon be complemented by neurokinin antagonists, which currently boast great efficacy for menopausal hot flashes. Hormonal options like transdermal estrogen are most likely to provide relief but gynecomastia may develop.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lin KL, Talmor B, Crumbaker M, et al. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025. PMID: 40397707. doi:10.1210/clinem/dgaf302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。